Avalo Therapeutics, Inc. · NASDAQ:AVTX
Doyle Mittie sold 679 Avalo Therapeutics, Inc. shares (Form 4)
Traded Aug 28, 2026 · Filed Sep 1, 2026
On Aug 28, 2026, Doyle Mittie (Chief Medical Officer) sold 679 Avalo Therapeutics, Inc. shares at US$20.00 for US$13,580 under a trading plan, leaving 51,776 shares. Filed Sep 1, 2026 (Form 4).
- Sold
- 679 shares
- Price
- US$20.00
- Value
- US$13,580
- Holding after
- 51,776 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Chief Medical Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Aug 28, 2026 | Common Stock | Option exercise | 679 | US$8.04 | 52,455 | Direct |
| Aug 28, 2026 | Common Stock | Sale | 679 | US$20.00 | 51,776 | Direct |
Source
Related
- Avalo Therapeutics, Inc.
- Doyle Mittie
- Avalo Therapeutics, Inc. shareholders
- Form 4 · Doyle Mittie · Aug 19, 2026
- Form 4 · Doyle Mittie · Aug 12, 2026
- Form 4 · Doyle Mittie · Jul 29, 2026
- Form 4 · Doyle Mittie · Jul 2, 2026
- Form 4 · Doyle Mittie · Jun 25, 2026
- Form 4 · Sullivan Christopher Ryan · Sep 18, 2026
- Form 4 · Sullivan Christopher Ryan · Sep 11, 2026
- Form 4 · Sullivan Christopher Ryan · Aug 19, 2026
- Schedule 13G/A · Bvf Partners L P · Aug 14, 2026
- Schedule 13G/A · Nantahala Capital Management, LLC · Aug 14, 2026